glp 1 agonist therapy Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive GLP-1 Agonists in Cardiovascular Diseases:

This is particularly important, considering that Pfizer NYSE: PFE recently discontinued its oral GLP-1 treatment because of these issues

Updated July 2026 The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment

10.1161/CIRCULATIONAHA.106.675355 26 GersteinH

Bikmans insights on allulose and GLP-1 illustrate that we can enhance our wellness through various pathways, making sustainable choices that allow us to thrive

Increased lipase and alanine aminotransferase were noted in 3 (23.1%) and 1 (7.7%) of the patients, respectively, with none of those resulting in pancreatitis and/or cholelithiasis

Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M